DOI: https://doi.org/10.22141/2224-0551.7.67.2015.75100

Angelman Syndrome. Part 3 (Differential Diagnosis and Treatment)

O.Ye. Abaturov, L.L. Petrenko, O.L. Kryvusha

Abstract


The article discusses the problem of differential diagnosis and treatment of patients with Angelman syndrome (AS). It provides the most common syndromes with similar to AS phenotypes, the main differences between AS-like syndromes, indicating the causative gene. Much attention is given to the basic directions of treating patients with Angelman syndrome: organization of regime, syndromic treatment, providing psychological, speech therapy, orthopedic services, occupational therapy, activities aimed at social adaptation. This article contains the latest information about modern progressive directions of AS medical management. To optimize the diagnostic and therapeutic process, data about international Angelman syndrome foundations are shown.


Keywords


Angelman syndrome

References


Новоселова О.Г. Перспективы диагностики расстройств аутистического спектра у детей / О.Г. Новоселова, Г.А. Каркашадзе, Н.В. Журкова, О.И. Маслова // Вопросы современной педиатрии. 2014; 13 (3): 61-68.

Adam M.P., Conta J., Bean L.J.H. Mowat-Wilson Syndrome // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2007 Mar 28 [updated 2013 Nov 26]. PMID: 20301585.

Angriman M. Sleep in children with neurodevelopmental di­sabilities / M. Angriman, B. Caravale, L. Novelli, R. Ferri, O. Bruni // Neuropediatrics. 2015 Jun; 46(3): 199-210. doi: 10.1055/s-0035-1550151.

Ardinger H.H., Welsh H.I., Saunders C.J. Pitt-Hopkins Syndrome // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2012 Aug 30.

Arnaud M. Le syndrome Kabuki: mise au point et revue de la litterature / M. Arnaud, M. Barat-Houari, V. Gatinois et al. // Archives de Pediatrie. 2015 Jun; 22(6): 653-60. doi: 10.1016/j.arcped.2015.03.020.

Beaudet A.L. Angelman syndrome: Drugs to awaken a paternal gene // Nature. 2011 Dec 21; 481(7380): 150-2. doi: 10.1038/nature10784.

Bertossi C. Forkhead box G1 gene haploinsufficiency: an emer­ging cause of dyskinetic encephalopathy of infancy / C. Bertossi, M. Cassina, A. Cappellari et al. // Neuropediatrics. 2015 Feb; 46(1): 56-64. doi: 10.1055/s-0034-1395345.

Bilousova T.V. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model / T.V. Bilousova, L. Dansie, M. Ngo, J. Aye, J.R. Charles, D.W. Ethell, I.M. Ethell // J. Med. Genet. 2009 Feb; 46(2): 94-102. doi: 10.1136/jmg.2008.061796.

Bird L.M. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome / L.M. Bird, W.H. Tan, C.A. Bacino et al. // Am. J. Med. Genet. A. 2011 Dec; 155A(12): 2956-63. doi: 10.1002/ajmg.a.34297.

Braam W. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial / W. Braam, R. Didden, M.G. Smits, L.M. Curfs // J. Child Neurol. 2008 Jun; 23(6): 649-54. doi: 10.1177/0883073808314153.

Campbell I.M. Novel 9q34.11 gene deletions encompassing combinations of four Mendelian disease genes: STXBP1, SPTAN1, ENG, and TOR1A / I.M. Campbell, S.A. Yatsenko, P. Hixson et al. // Genet. Med. 2012 Oct; 14(10): 868-76. doi: 10.1038/gim.2012.65.

Christodoulou J., Ho G. MECP2-Related Disorders // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2001 Oct 03 [updated 2012 Jun 28]. PMID: 20301670.

Da Paz J.A. Mowat-Wilson syndrome: neurological and molecular study in seven patients / J.A. da Paz, C.A. Kim, M. Goossens, I. Giurgea, M.J. Marques-Dias // Arq. Neuropsiquiatr. 2015 Jan; 73(1): 12-7. doi: 10.1590/0004-282X20140182.

Dagli A.I., Mueller J., Williams C.A. Angelman Syndrome // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 1998 Sep 15 [updated 2015 May 14].PMID: 20301323.

De Leersnyder H. Smith-Magenis syndrome // Handb. Clin. Neurol. 2013; 111: 295-6. doi: 10.1016/B978-0-444-52891-9.00034-8.

Dentici M.L. Kabuki syndrome: clinical and molecular diagnosis in the first year of life / M.L. Dentici, A. Di Pede, F.R. Lepri et al. // Arch. Dis. Child. 2015 Feb; 100(2): 158-64. doi: 10.1136/archdischild-2013-305858.

Dornelles-Wawruk H. Complex phenotype associated with 17q21.31 microdeletion / H. Dornelles-Wawruk, A. Pic-Taylor, C. Rosenberg, A.C. Krepischi, H.P. Safatle, I. Ferrari, J.F. Mazzeu // Mol. Syndromol. 2013 Sep; 4(6): 297-301. doi: 10.1159/000354120.

Dziembowska M. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline / M. Dziembowska, D.I. Pretto, A. Janusz et al. // Am. J. Med. Genet. A. 2013 Aug; 161A(8): 1897-903. doi: 10.1002/ajmg.a.36023.

Grieco J.C. An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome / J.C. Grieco, S.L. Ciarlone, M. Gieron-Korthals et al. // BMC Neurol. 2014 Dec 10; 14(1): 232. doi: 10.1186/s12883-014-0232-x.

Grigg-Damberger M., Ralls F. Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders // Curr. Opin. Pulm. Med. 2013 Nov; 19(6): 616-25. doi: 10.1097/MCP.0b013e328365ab89.

Heald M. Discrimination training reduces high rate social approach behaviors in Angelman syndrome: proof of principle / M. Heald, D. Allen, D. Villa, C. Oliver // Res. Dev. Disabil. 2013 May; 34(5): 1794-803. doi: 10.1016/j.ridd.2013.02.012.

Huang H.S. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons / H.S. Huang, J.A. Allen, A.M. Mabb et al. // Nature. 2011 Dec 21; 481(7380): 185-9. doi: 10.1038/nature10726.

Jurecka A. Adenylosuccinate lyase deficiency / A. Jurecka, M. Zikanova, S. Kmoch, A. Tylki-Szymańska // J. Inherit. Metab. Dis. 2015 Mar; 38(2): 231-42. doi: 10.1007/s10545-014-9755-y.

Kleefstra T., Nillesen W.M., Yntema H.G. Kleefstra Syndrome // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2010 Oct 5 [updated 2015 May 7]. PMID: 20945554.

Kolevzon A. Phelan-McDermid syndrome: a review of the lite­rature and practice parameters for medical assessment and monito­ring / A. Kolevzon, B. Angarita, L. Bush et al. // J. Neurodev. Disord. 2014; 6(1): 39. doi: 10.1186/1866-1955-6-39.

Koolen D.A. Mutations in the chromatin modifier gene ­KANSL1 cause the 17q21.31 microdeletion syndrome / D.A. Koolen, J.M. Kramer, K. Neveling et al. // Nat. Genet. 2012 Apr 29; 44(6): 639-41. doi: 10.1038/ng.2262.;

Meng L. Towards a therapy for Angelman syndrome by targe­ting a long non-coding RNA / L. Meng, A.J. Ward, S. Chun, C.F. Bennett, A.L. Beaudet, F. Rigo // Nature. 2015 Feb 19; 518(7539): 409-12. doi: 10.1038/nature13975.

Motobayashi M. Neurodevelopmental features in 2q23.1 microdeletion syndrome: report of a new patient with intractable seizures and review of literature / M. Motobayashi, A. Nishimura-Tadaki, Y. Inaba et al. // Am. J. Med. Genet. A. 2012 Apr; 158A(4): 861-8. doi: 10.1002/ajmg.a.35235.

Mullegama S.V. Phenotypic and molecular convergence of 2q23.1 deletion syndrome with other neurodevelopmental syndromes associated with autism spectrum disorder / S.V. Mullegama, J.T. Alaimo, L. Chen, S.H. Elsea // Int. J. Mol. Sci. 2015 Apr 7; 16(4): 7627-43. doi: 10.3390/ijms16047627.

Mullegama S.V. Reciprocal deletion and duplication at 2q23.1 indicates a role for MBD5 in autism spectrum disorder / S.V. Mullegama, J.A. Rosenfeld, C. Orellana et al. // Eur. J. Hum. Genet. 2014 Jan; 22(1): 57-63. doi: 10.1038/ejhg.2013.67.

Paciorkowski A.R. MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways / A.R. Paciorkowski, R.N. Traylor, J.A. Rosenfeld et al. // Neurogenetics. 2013 May; 14(2): 99-111. doi: 10.1007/s10048-013-0356-y.

Panda A.K., Kar S.K., Gopinath G. Angelman syndrome in three biological siblings: Focusing on the neuropsychiatric domain // J. Pediatr. Neurosci. 2013 Sep; 8(3): 213-6. doi: 10.4103/1817-1745.123674.

Pelc K. Epilepsy in Angelman syndrome / K. Pelc, S.G. Boyd, G. Cheron, B. Dan // Seizure. 2008 Apr; 17(3): 211-7. doi: http://dx.doi.org/10.1016/j.seizure.2007.08.004.

Pescosolido M.F. Genetic and phenotypic diversity of NHE6 mutations in Christianson syndrome / M.F. Pescosolido, D.M. Stein, M. Schmidt et al. // Ann. Neurol. 2014 Oct; 76(4): 581-93. doi: 10.1002/ana.24225.

Peters S.U. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid / S.U. Peters, L.M. Bird, V. Kimonis et al. // Am. J. Med. Genet. A. 2010 Aug; 152A(8): 1994-2001. doi: 10.1002/ajmg.a.33509.

Peters S.U., Byiers B.J., Symons F.J. Diurnal Salivary Cortisol and Regression Status in MECP2 Duplication Syndrome // J. Child. Neurol. 2015 May 21. pii: 0883073815585577.

Phelan K., Rogers R.C. Phelan-McDermid Syndrome // Pagon R.A., Adam M.P., Ardinger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2005 May 11 [updated 2011 Aug 25].

Puffenberger E.G. A homozygous missense mutation in HERC2 associated with global developmental delay and autism spectrum disorder / E.G. Puffenberger, R.N. Jinks, H. Wang et al. // Hum. Mutat. 2012 Dec; 33(12): 1639-46. doi: 10.1002/humu.22237.

Ramocki M.B., Tavyev Y.J., Peters S.U. The MECP2 duplication syndrome // Am. J. Med. Genet. A. 2010 May; 152A(5): 1079-88. doi: 10.1002/ajmg.a.33184.

Schwichtenberg A.J., Malow B.A. Melatonin Treatment in Children with Developmental Disabilities // Sleep Med. Clin. 2015 Jun; 10(2): 181-187. doi: 10.1016/j.jsmc.2015.02.008.

Stevenson R.E. Alpha-Thalassemia X-Linked Intellectual Disability Syndrome // Pagon R.A., Adam M.P., Ardin­ger H.H., Wallace S.E., Amemiya A., Bean L.J.H., Bird T.D., Dolan C.R., Fong C.T., Smith R.J.H., Stephens K., editors // GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. 2000 Jun 19 [updated 2014 Nov 06].PMID:

Summers J.A. A combined behavioral/pharmacological treatment of sleep-wake schedule disorder in Angelman syndrome / J.A. Summers, P.S. Lynch, J.C. Harris, J.C. Burke, D.B. Allison, L. Sandler // J. Dev. Behav. Pediatr. 1992 Aug; 13(4): 284-7. PMID: 1506469.

Tan W.H. If not Angelman, what is it? A review of Angelman-like syndromes / W.H. Tan, L.M. Bird, R.L. Thibert, C.A. Williams // Am. J. Med. Genet. A. 2014 Apr; 164A(4): 975-92. doi: 10.1002/ajmg.a.36416.

Thibert R.L. Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options / R.L. Thibert, K.D. Conant, E.K. Braun et al. // Epilepsia. 2009 Nov; 50(11): 2369-76. doi: 10.1111/j.1528-1167.2009.02108.x.

Williams C.A., Driscoll D.J., Dagli A.I. Clinical and genetic aspects of Angelman syndrome // Genet. Med. 2010 Jul; 12(7): 385-95. doi: 10.1097/GIM.0b013e3181def138.






Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта